文献速递乳腺癌

乳腺癌中LAG-3+肿瘤浸润淋巴细胞的临床相关性与PD-1/PD-L1+肿瘤的关联

LAG-3+ tumor infiltrating lymphocytes in breast cancer: clinical correlates and association with PD-1/PD-L1+ tumors.
PubMed 文献 · Ann Oncol · 2017-01-01

该研究在4322例乳腺癌原发切除标本中评估LAG-3表达及其预后价值,并分析其与PD-1、PD-L1的关联。LAG-3+ iTILs见于验证集的11%病例,与不良预后因素相关,但多因素分析显示与改善的乳腺癌特异性生存相关(HR 0.71),尤其在ER阴性患者中(HR 0.50)。53%的PD-L1+和61%的PD-1+病例也阳性表达LAG-3+ iTILs。

要点

  • LAG-3+ iTILs见于11%的验证集乳腺癌病例,且与年轻、大肿瘤、高增殖、HER2E和基底样亚型相关。
  • 多因素分析中LAG-3+ iTILs与改善的乳腺癌特异性生存相关(HR 0.71),ER阴性患者更显著(HR 0.50)。
  • 53%的PD-L1+和61%的PD-1+病例也阳性表达LAG-3+ iTILs,支持联合免疫检查点阻断策略。

核心结论

  • LAG-3+ iTILs富集于雌激素受体阴性乳腺癌,是独立的有利预后因素。
  • 高比例的PD-1/PD-L1+肿瘤共浸润LAG-3+ TILs,支持潜在的免疫检查点联合阻断策略作为乳腺癌治疗选择。

研究设计与样本

  • 研究采用免疫组化评估两个组织芯片系列共4322例乳腺癌原发切除标本(训练集N=330,验证集N=3992)的LAG-3表达,并关联详细的临床病理、生物标志物和长期临床结局数据。
  • PD-1和PD-L1表达也通过免疫组化评估;表达LAG-3或PD-1的间质或上皮内肿瘤浸润淋巴细胞(sTILs或iTILs)通过绝对计数评估;PD-L1表达评估为每个核心阳性癌细胞的百分比。
  • 生存分析采用Kaplan-Meier曲线和Cox比例风险模型。

主要发现

  • 在训练集锁定解释截断值后,验证集中11%的病例发现LAG-3+ iTILs。
  • 在两个集中,LAG-3+ iTILs与不良预后因素显著相关:年轻年龄、大肿瘤尺寸、高增殖、HER2E和基底样乳腺癌亚型。
  • 多因素分析中,LAG-3+ iTILs的乳腺癌患者乳腺癌特异性生存显著改善(HR:0.71,95% CI 0.56-0.90),尤其在雌激素受体阴性患者中(HR:0.50,95% CI 0.36-0.69)。
  • 53%的PD-L1+和61%的PD-1+病例也阳性表达LAG-3+ iTILs。
  • LAG-3+和CD8+ iTILs同时浸润与乳腺癌特异性生存增加显著相关(HR:0.49,95% CI 0.32-0.74)。

关键数值与推荐

  • LAG-3+ iTILs在验证集中的阳性率为11%。
  • LAG-3+ iTILs与乳腺癌特异性生存改善相关:HR 0.71(95% CI 0.56-0.90)。
  • ER阴性患者中LAG-3+ iTILs与乳腺癌特异性生存改善相关:HR 0.50(95% CI 0.36-0.69)。
  • LAG-3+和CD8+ iTILs同时浸润与乳腺癌特异性生存改善相关:HR 0.49(95% CI 0.32-0.74)。
  • 53%的PD-L1+和61%的PD-1+病例也阳性表达LAG-3+ iTILs。

临床怎么用

  • LAG-3+ iTILs可作为乳腺癌的独立有利预后因素,尤其在ER阴性患者中。
  • PD-1/PD-L1+肿瘤中高比例共浸润LAG-3+ TILs,支持评估免疫检查点联合阻断策略的临床试验。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Novel immune checkpoint blockade strategies are being evaluated in clinical trials and include targeting the lymphocyte activation gene 3 (LAG-3) checkpoint, alone or in combination with PD-1/PD-L1 blockade. We investigated LAG-3 expression and its prognostic value in a large series of breast cancer patients, and correlated LAG-3 expression with key biomarkers including PD-1 and PD-L1. EXPERIMENTAL DESIGN: LAG-3 expression was evaluated by immunohistochemistry on two tissue microarray series incorporating 4322 breast cancer primary excision specimens (N = 330 in the training and N= 3992 in the validation set) linked to detailed clinicopathologic, biomarker and long-term clinical outcome data. PD-1 and PD-L1 expressions were also evaluated by immunohistochemistry. Stromal or intra-epithelial tumor infiltrating lymphocytes (sTILs or iTILs) expressing LAG-3 or PD-1 were assessed by absolute count. PD-L1 expression was evaluated as the percentage of positive carcinoma cells per core. Kaplan-Meier curves and Cox proportional hazard models were used for survival analyses. RESULTS: After locking down interpretation cut-offs on the training set, LAG-3+ iTILs were found in 11% of cases in the validation set. In both sets, LAG-3+ iTILs were significantly associated with negative prognostic factors: young age, large tumor size, high proliferation, HER2E and basal-like breast cancer subtypes. In multivariate analyses, breast cancer patients with LAG-3+ iTILs had a significantly improved breast cancer-specific survival [hazard ratio (HR): 0.71, 95% CI 0.56-0.90], particularly among estrogen receptor-negative patients (HR: 0.50, 95% CI 0.36-0.69). Furthermore, we found that 53% of PD-L1+ and 61% of PD-1+ cases were also positive for LAG-3+ iTILs. Concurrent infiltration of LAG-3+ and CD8+ iTILs was significantly associated with increased breast cancer-specific survival (HR: 0.49, 95% CI 0.32-0.74). CONCLUSION: LAG-3+ iTILs are enriched in estrogen receptor-negative breast cancers and represent an independent favorable prognostic factor. In addition, a high proportion of PD-1/PD-L1+ tumors are co-infiltrated with LAG-3+ TILs, supporting potential immune checkpoint blockade combination strategies as a treatment option for breast cancer patients.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Burugu S, Gao D, Leung S, et al. LAG-3+ tumor infiltrating lymphocytes in breast cancer: clinical correlates and association with PD-1/PD-L1+ tumors. Ann Oncol. 2017. PMID: 29045526. doi:10.1093/annonc/mdx557

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。